New ADHD drug shows promise in small trial for adult men
NCT ID NCT01939353
First seen Apr 30, 2026 · Last updated May 17, 2026 · Updated 4 times
Summary
This study tested a new medication called EB-1020 SR (centanafadine) in 45 adult men with ADHD. The goal was to see if it could reduce ADHD symptoms like inattention and hyperactivity. Participants took the drug for 4 weeks, and researchers measured changes using a standard ADHD rating scale. The trial was exploratory, meaning it aimed to gather initial data on effectiveness and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT ADHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Bradenton, Florida, 34201, United States
-
Study site
Maitland, Florida, 32751, United States
-
Study site
Las Vegas, Nevada, 89128, United States
Conditions
Explore the condition pages connected to this study.